Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 27%
Hold 53%
Sell 7%
Strong Sell 0%

Bulls say

Amgen has demonstrated significant growth in its product sales, with a reported 40% increase in 3Q25 compared to 3Q24, and 16 products achieving double-digit sales growth during the same period. The company's investment in research and development is poised to exceed 20% growth in 2025, indicating a strong commitment to innovation and market expansion. Additionally, Amgen raised its fiscal year 2025 revenue guidance to a range of $35.8-$36.6 billion, underscoring its sustained strength in established franchises and new product launches.

Bears say

The analysis indicates that Amgen is projected to experience minimal revenue growth of approximately 1% in 2026 compared to 2025, significantly impacted by anticipated declines in sales for major products like Prolia and Xgeva, which are expected to drop by about 28% and 39%, respectively. While there are emerging products with potential, such as MariTide and olpasiran, their ability to mitigate the erosion of revenue from existing therapies remains uncertain, especially given negative developments from trials. Additionally, the company faces structural challenges due to upcoming losses of exclusivity for key drug franchises, which raises concerns about the sustainability of long-term growth drivers.

Amgen (AMGN) has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 27% recommend Buy, 53% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 15 analysts, Amgen (AMGN) has a Hold consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $343.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $343.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.